Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Annales De Medecine Interne
|
August 12, 2003
Aseptic meningitis associated with intravenous administration of dexchlorpheniramine
Matthieu Lafaurie, Adrien Dixmier, Jean-Michel Molina
Lung Cancer (Amsterdam, Netherlands)
|
December 26, 2021
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010
Didier Debieuvre, Charles Dayen, Adrien Dixmier, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
December 3, 2013
Comorbidities of COPD
Arnaud Cavaillès, Graziella Brinchault-Rabin, Adrien Dixmier, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
March 1, 2019
Women and COPD: do we need more evidence?
Christophe Gut-Gobert, Arnaud Cavaillès, Adrien Dixmier, et al.
Oncoimmunology
|
April 15, 2025
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
The European Respiratory Journal
|
October 28, 2017
Association between lung cancer somatic mutations and occupational exposure in never-smokers
Christophe Paris, Pascal Do, Bénédicte Mastroianni, et al.
The European Respiratory Journal
|
February 7, 2015
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
Sébastien Couraud, Pierre-Jean Souquet, Christophe Paris, et al.
JTO Clinical and Research Reports
|
December 31, 2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Valérie Gounant, Laurent Greillier, Céline Mascaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Alexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
Oncoimmunology
|
January 18, 2021
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Annales De Medecine Interne
|
August 12, 2003
Aseptic meningitis associated with intravenous administration of dexchlorpheniramine
Matthieu Lafaurie, Adrien Dixmier, Jean-Michel Molina
Lung Cancer (Amsterdam, Netherlands)
|
December 26, 2021
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010
Didier Debieuvre, Charles Dayen, Adrien Dixmier, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
December 3, 2013
Comorbidities of COPD
Arnaud Cavaillès, Graziella Brinchault-Rabin, Adrien Dixmier, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
March 1, 2019
Women and COPD: do we need more evidence?
Christophe Gut-Gobert, Arnaud Cavaillès, Adrien Dixmier, et al.
Oncoimmunology
|
April 15, 2025
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
The European Respiratory Journal
|
October 28, 2017
Association between lung cancer somatic mutations and occupational exposure in never-smokers
Christophe Paris, Pascal Do, Bénédicte Mastroianni, et al.
The European Respiratory Journal
|
February 7, 2015
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
Sébastien Couraud, Pierre-Jean Souquet, Christophe Paris, et al.
JTO Clinical and Research Reports
|
December 31, 2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Valérie Gounant, Laurent Greillier, Céline Mascaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Alexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
Oncoimmunology
|
January 18, 2021
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
Page
of 2